Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zhiyao Fan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-3515-5758; OpenAlex author ID A5080336977. Sources: OpenAlex.

Their work

Papers
29 (first author 11, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2018: 4 papers · 2019: 4 papers · 2020: 8 papers · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 4 papers · 2025: 3 papers

Papers 29

  1. Mitochondria-centric lipid metabolism and inter-organelle crosstalk in pancreatic Cancer: Unveiling novel therapies. Co-author DOI 10.1016/j.canlet.2025.217965↗
  2. Genetic association of lipid-lowering drug target genes with pancreatic cancer: a Mendelian randomization study. First author DOI 10.1038/s41598-025-87490-x↗
  3. [Clinicopathologic features and lipid profile characteristics of early-onset pancreatic cancer]. First author DOI 10.3760/cma.j.cn112139-20240826-00397↗
  4. Crosstalk between pancreatic cancer and adipose tissue: Molecular mechanisms and therapeutic implications. First author DOI 10.1016/j.bbrc.2024.151012↗
  5. ZFHX3 methylation in peripheral blood monocytes as a potential biomarker for pancreatic cancer detection. First author DOI 10.1016/j.pan.2024.05.529↗
  6. Comment on "Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection". First author DOI 10.1097/as9.0000000000000376↗
  7. [Research status of the tumor stroma ratio in prognosis and treatment of pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20240414-00183↗
  8. FABP4 in macrophages facilitates obesity-associated pancreatic cancer progression via the NLRP3/IL-1β axis. Co-author DOI 10.1016/j.canlet.2023.216403↗
  9. Fibrinogen-to-prealbumin ratio: A new prognostic marker of resectable pancreatic cancer. First author DOI 10.3389/fonc.2023.1149942↗
  10. COL17A1 facilitates tumor growth and predicts poor prognosis in pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2022.09.049↗
  11. [Changes of serum lipid profiles and the correlation analysis in clinic-pathological features of pancreatic cancer patients]. First author DOI 10.3760/cma.j.cn112139-20220209-00054↗
  12. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Co-author DOI 10.1016/j.bbcan.2020.188409↗
  13. Exosomal linc-ROR mediates crosstalk between cancer cells and adipocytes to promote tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.omtn.2021.06.001↗
  14. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Co-author DOI 10.1002/cam4.2895↗
  15. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2020.02.016↗
  16. HNF-1a promotes pancreatic cancer growth and apoptosis resistance via its target gene PKLR. Co-author DOI 10.1093/abbs/gmz169↗
  17. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Co-author DOI 10.1177/1073274820915947↗
  18. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-020-00958-3↗
  19. Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08301-3↗
  20. ASO Author Reflections: C-Reactive Protein/Lymphocyte Ratio as a Promising Marker for Predicting Survival in Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08335-7↗
  21. Lewis antigen‑negative pancreatic cancer: An aggressive subgroup. Co-author DOI 10.3892/ijo.2020.4989↗
  22. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cance… First author DOI 10.1002/cam4.2463↗
  23. Kras G12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.01.013↗
  24. Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes. First author DOI 10.1097/mpa.0000000000001338↗
  25. The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. Co-author DOI 10.2147/cmar.s211363↗
  26. Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-018-2235-8↗
  27. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.01.017↗
  28. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. First author DOI 10.1016/j.pan.2018.08.003↗
  29. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. Co-author DOI 10.1186/s13045-017-0551-7↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hanxiang Zhan · 7 shared papers, 2022–2025 · strength 2.20
  2. Xianjun Yu · 17 shared papers, 2018–2021 · strength 1.67
  3. Chen Liu · 17 shared papers, 2018–2021 · strength 1.67
  4. Guopei Luo · 17 shared papers, 2018–2021 · strength 1.67
  5. Kaizhou Jin · 16 shared papers, 2018–2021 · strength 1.52
  6. Yitao Gong · 11 shared papers, 2019–2021 · strength 1.19
  7. He Cheng · 12 shared papers, 2018–2021 · strength 1.15
  8. Quanxing Ni · 8 shared papers, 2018–2021 · strength 0.80
  9. Chao Yang · 9 shared papers, 2018–2020 · strength 0.76
  10. Yunzhen Qian · 7 shared papers, 2020–2021 · strength 0.75
  11. Yongzheng Li · 4 shared papers, 2021–2024 · strength 0.67
  12. Hanxiang Zhan · 4 shared papers, 2021–2024 · strength 0.67
  13. Xin Gao · 2 shared papers, 2024–2025 · strength 0.66
  14. Kun Fan · 7 shared papers, 2018–2020 · strength 0.60
  15. Chaoyu Pang · 2 shared papers, 2024–2025 · strength 0.51
  16. Jian Yang · 3 shared papers, 2021–2023 · strength 0.46
  17. Bin Zhou · 2 shared papers, 2021–2024 · strength 0.43
  18. Bohan Su · 1 shared paper, 2025 · strength 0.37
  19. Runxian Wang · 1 shared paper, 2025 · strength 0.33
  20. Boyu Diao · 1 shared paper, 2024 · strength 0.31
  21. Jin Xu · 3 shared papers, 2018–2020 · strength 0.27
  22. Zhaowei Sun · 2 shared papers, 2021–2022 · strength 0.27
  23. Yiyin Zhang · 3 shared papers, 2018 · strength 0.22
  24. Guangyong Zhang · 1 shared paper, 2023 · strength 0.19
  25. Cheng He · 2 shared papers, 2018–2019 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.